Generic Name and Formulations:
Bromfenac 0.075%; oph soln; contains benzalkonium chloride.
Sun Pharmaceutical Industries
Indications for BROMSITE:
Post-operative inflammation and prevention of ocular pain following cataract surgery.
≥18yrs: 1 drop in affected eye twice daily starting 1 day before surgery, continued on day of surgery, and for 14 days post-op. May be given with other topical ophthalmics (eg, alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics); administer at least 5 mins apart.
<18yrs: not established.
Bleeding tendencies. May slow or delay wound healing. Potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, other NSAIDs. Complicated/repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Risk of corneal adverse events may be increased if used >24hrs before surgery, or beyond 14-days post-op. Contact lenses (remove during therapy). Pregnancy: avoid during late pregnancy. Nursing mothers.
Concomitant topical NSAIDs and corticosteroids may potentiate healing problems. Caution with concomitant drugs that prolong bleeding time.
Anterior chamber inflammation, headache, vitreous floaters, iritis, eye pain, ocular hypertension; keratitis, corneal reactions (eg, epithelial breakdown, thinning, erosion, ulceration/perforation).
Neurology Advisor Articles
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis
- Early Onset of Efficacy After Erenumab Treatment in Chronic and Episodic Migraines